Copy to clipboard 
ORTHOWORLD estimates Smith & Nephew 2Q17 orthopaedic revenue of US $834.0MM, +1.1% from 2Q16, and 1H17 revenue of $1,660.9MM, +2.0% vs. 1H16. ORTHOWORLD estimates for segment growth follow.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Reconstruction | $417.9 | $411.9 | $6.0 | 1.5% |
| Hip | $150.0 | $153.0 | -$3.0 | -2.0% |
| Knee | $254.0 | $245.8 | $8.2 | 3.3% |
| Extremities | $13.8 | $13.1 | $0.8 | 5.8% |
| Trauma | $113.2 | $105.9 | $7.2 | 6.8% |
| Arthroscopy/Soft Tissue | $303.0 | $307.0 | -$4.0 | -1.3% |
| Total | $834.0 | $824.8 | $9.2 | 1.1% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Reconstruction | $834.9 | $816.4 | $18.4 | 2.3% |
| Hip | $302.0 | $306.0 | -$4.0 | -1.3% |
| Knee | $505.9 | $484.8 | $21.1 | 4.4% |
| Extremities | $26.9 | $25.6 | $1.3 | 5.0% |
| Trauma | $220.1 | $207.4 | $12.7 | 6.1% |
| Arthroscopy/Soft Tissue | $606.0 | $604.0 | $2.0 | 0.3% |
| Total | $1,660.9 | $1,627.8 | $33.1 | 2.0% |
Performance highlights:
- Launched total knee application for NAVIO robotic-assisted surgery; encouraged to see upward trend in utilization; pipeline contains expanded indications (hip, sports medicine)
- Multiple NAVIO units sold in India
- Growth supported by NAVIO, Q-FIX shoulder repair, ULTRABUTTON knee repair, TRIGEN INTERTAN hip fracture system, JOURNEY II total and LEGION revision knees
- Received a small tender order in Gulf States that supported Trauma and Extremities growth
- Arthroscopy impacted by continued softness in legacy resection, slower uptake on WEREWOLF Coblation; for the latter, issues are behind them and growth is expected in 2H17
- Newly-launched Monolithic Sleeved stem for REDAPT revision hip expected to contribute in 2H17
- Excited about shift to joint procedures in ASCs, where SNN sports med and ENT products are already in use; can leverage to capture larger share of knee market, and include NAVIO and PICO/ACTICOAT
- At 3-year anniversary of ArthroCare acquisition, all targets are met: cost/revenue synergies, $85MM profile level, return on invested capital
- Will continue to fine-tune Syncera, which requires only a small amount of resources; still not seeing any impact of the Comprehensive Care for Joint Replacement yet
- After quarter’s close, announced 3-year partnership with Imperial College London to research meniscus function and the interaction of ligaments in the stabilization of the knee joint to support the design of devices to treat worn cartilage
Sources: Smith & Nephew plc; ORTHOWORLD estimates
ORTHOWORLD estimates Smith & Nephew 2Q17 orthopaedic revenue of US $834.0MM, +1.1% from 2Q16, and 1H17 revenue of $1,660.9MM, +2.0% vs. 1H16. ORTHOWORLD estimates for segment growth follow.
Q17
Q16
$ Change
% Change
Joint...
ORTHOWORLD estimates Smith & Nephew 2Q17 orthopaedic revenue of US $834.0MM, +1.1% from 2Q16, and 1H17 revenue of $1,660.9MM, +2.0% vs. 1H16. ORTHOWORLD estimates for segment growth follow.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Joint Reconstruction | $417.9 | $411.9 | $6.0 | 1.5% |
| Hip | $150.0 | $153.0 | -$3.0 | -2.0% |
| Knee | $254.0 | $245.8 | $8.2 | 3.3% |
| Extremities | $13.8 | $13.1 | $0.8 | 5.8% |
| Trauma | $113.2 | $105.9 | $7.2 | 6.8% |
| Arthroscopy/Soft Tissue | $303.0 | $307.0 | -$4.0 | -1.3% |
| Total | $834.0 | $824.8 | $9.2 | 1.1% |
| 1H17 | 1H16 | $ Change | % Change | |
| Joint Reconstruction | $834.9 | $816.4 | $18.4 | 2.3% |
| Hip | $302.0 | $306.0 | -$4.0 | -1.3% |
| Knee | $505.9 | $484.8 | $21.1 | 4.4% |
| Extremities | $26.9 | $25.6 | $1.3 | 5.0% |
| Trauma | $220.1 | $207.4 | $12.7 | 6.1% |
| Arthroscopy/Soft Tissue | $606.0 | $604.0 | $2.0 | 0.3% |
| Total | $1,660.9 | $1,627.8 | $33.1 | 2.0% |
Performance highlights:
- Launched total knee application for NAVIO robotic-assisted surgery; encouraged to see upward trend in utilization; pipeline contains expanded indications (hip, sports medicine)
- Multiple NAVIO units sold in India
- Growth supported by NAVIO, Q-FIX shoulder repair, ULTRABUTTON knee repair, TRIGEN INTERTAN hip fracture system, JOURNEY II total and LEGION revision knees
- Received a small tender order in Gulf States that supported Trauma and Extremities growth
- Arthroscopy impacted by continued softness in legacy resection, slower uptake on WEREWOLF Coblation; for the latter, issues are behind them and growth is expected in 2H17
- Newly-launched Monolithic Sleeved stem for REDAPT revision hip expected to contribute in 2H17
- Excited about shift to joint procedures in ASCs, where SNN sports med and ENT products are already in use; can leverage to capture larger share of knee market, and include NAVIO and PICO/ACTICOAT
- At 3-year anniversary of ArthroCare acquisition, all targets are met: cost/revenue synergies, $85MM profile level, return on invested capital
- Will continue to fine-tune Syncera, which requires only a small amount of resources; still not seeing any impact of the Comprehensive Care for Joint Replacement yet
- After quarter’s close, announced 3-year partnership with Imperial College London to research meniscus function and the interaction of ligaments in the stabilization of the knee joint to support the design of devices to treat worn cartilage
Sources: Smith & Nephew plc; ORTHOWORLD estimates
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
